A publication referencing ipamorelin appeared on April 27, 2026, in the International Journal of Molecular Sciences. The paper is titled "Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives." Ipamorelin remains an unapproved compound used only in research settings. The publication is listed under PubMed ID 42123471. No specific findings, data, or conclusions about ipamorelin were provided beyond the publication title and journal listing. This entry reflects only the appearance of the paper and does not describe its content or results. Readers interested in the topic can access the publication directly through the linked PubMed source for full details. This brief does not summarize or interpret any efficacy, safety outcomes, or clinical recommendations from the paper. It serves solely to note that a new peer reviewed publication referencing ipamorelin has been indexed. For general background on ipamorelin, including its regulatory status and research context, readers can consult the compound overview.
Ipamorelin Featured in New Peptide Review Publication
Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.
See the full ipamorelin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42123471/